{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:19:07Z","timestamp":1762431547877},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10354-018-0658-7","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:33:12Z","timestamp":1536046392000},"page":"25-32","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease"],"prefix":"10.1007","volume":"169","author":[{"given":"Alexander Stephan","family":"Kroiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"658_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10689-004-2155-y","volume":"4","author":"I Brink","year":"2005","unstructured":"Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4:61\u20138.","journal-title":"Fam Cancer"},{"key":"658_CR2","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1210\/jc.2009-1248","volume":"94","author":"HJ Timmers","year":"2009","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Chen CC, Whatley M, Ling A, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluorodeoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J\u00a0Clin Endocrinol Metab. 2009;94:4757\u201367.","journal-title":"J Clin Endocrinol Metab"},{"key":"658_CR3","first-page":"217","volume":"43","author":"JC Sisson","year":"1999","unstructured":"Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q\u00a0J Nucl Med. 1999;43:217\u201323.","journal-title":"Q J Nucl Med"},{"key":"658_CR4","first-page":"561","volume":"21","author":"CA Hoefnagel","year":"1994","unstructured":"Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med. 1994;21:561\u201381.","journal-title":"Eur J Nucl Med"},{"key":"658_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/BF03401287","volume":"12","author":"V Rufini","year":"2013","unstructured":"Rufini V, Treglia G, Perotti G, Giordano A. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas. Hormones (Athens). 2013;12:58\u201368.","journal-title":"Hormones (Athens)"},{"key":"658_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2222010622","volume":"222","author":"S Hoegerle","year":"2002","unstructured":"Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et\u00a0al. Pheochromocytomas: detection with 18F DOPA whole body PET\u2014initial results. Radiology. 2002;222:507\u201312.","journal-title":"Radiology"},{"key":"658_CR7","first-page":"679","volume":"39","author":"BL Shulkin","year":"1998","unstructured":"Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J\u00a0Nucl Med. 1998;39:679\u201388.","journal-title":"J Nucl Med"},{"key":"658_CR8","first-page":"1352","volume":"38","author":"A Leung","year":"1997","unstructured":"Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, et\u00a0al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J\u00a0Nucl Med. 1997;38:1352\u20137.","journal-title":"J Nucl Med"},{"key":"658_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2967\/jnumed.107.047738","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J\u00a0Nucl Med. 2008;49:1232\u20137.","journal-title":"J Nucl Med"},{"key":"658_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1148\/radiology.199.3.8637999","volume":"199","author":"BL Shulkin","year":"1996","unstructured":"Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2\u2011[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743\u201350.","journal-title":"Radiology"},{"key":"658_CR11","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1200\/JCO.2008.20.5732","volume":"27","author":"DR Taggart","year":"2009","unstructured":"Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J\u00a0Clin Oncol. 2009;27:5343\u20139.","journal-title":"J Clin Oncol"},{"key":"658_CR12","first-page":"32","volume":"37","author":"M Bergstr\u00f6m","year":"1996","unstructured":"Bergstr\u00f6m M, Eriksson B, Oberg K, Sundin A, Ahlstr\u00f6m H, Lindner KJ, et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J\u00a0Nucl Med. 1996;37:32\u20137.","journal-title":"J Nucl Med"},{"key":"658_CR13","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","volume":"39","author":"G Treglia","year":"2012","unstructured":"Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a\u00a0meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"658_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12149-017-1162-7","volume":"31","author":"AS Kroiss","year":"2017","unstructured":"Kroiss AS, Uprimny C, Shulkin BL, Frech A, Tilg H, Gasser RW, et al. Compared to 123I-MIBG SPECT\/CT, 18F-DOPA PET\/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma. Ann Nucl Med. 2017;31:357\u201365.","journal-title":"Ann Nucl Med"},{"key":"658_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00259-011-1938-2","volume":"39","author":"A Piccardo","year":"2012","unstructured":"Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET\/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a\u00a0pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"658_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J\u00a0Nucl Med. 2007;48:508\u201318.","journal-title":"J Nucl Med"},{"key":"658_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40:514\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"658_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/RLU.0000000000001674","volume":"42","author":"H Jing","year":"2017","unstructured":"Jing H, Li F, Wang L, Wang Z, Li W, Huo L, et\u00a0al. Comparison of the 68Ga-DOTATATA PET\/CT, FDG PET\/CT, and MIBG SPECT\/CT in the Evaluation of Suspected Primary Pheochromocytomas and Paragangliomas. Clin Nucl Med. 2017;42:525\u20139.","journal-title":"Clin Nucl Med"},{"key":"658_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00259-010-1720-x","volume":"38","author":"A Kroiss","year":"2011","unstructured":"Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38:865\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"658_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00259-014-2892-6","volume":"42","author":"A Kroiss","year":"2015","unstructured":"Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. 68Ga-DOTATOC PET\/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to 123I-MIBG SPECT\/CT. Eur J Nucl Med Mol Imaging. 2015;42:33\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"658_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2967\/jnumed.112.115485","volume":"54","author":"P Sharma","year":"2013","unstructured":"Sharma P, Thakar A, Suman KCS, Dhull VS, Singh H, Naswa N, et al. 68Ga-DOTANOC PET\/CT for baseline evaluation of patients with head and neck paraganglioma. J\u00a0Nucl Med. 2013;54:841\u20137.","journal-title":"J Nucl Med"},{"key":"658_CR22","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","volume":"43","author":"I Janssen","year":"2016","unstructured":"Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, et al. PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43:1784\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"658_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2214\/ajr.181.4.1811115","volume":"181","author":"T Pfluger","year":"2003","unstructured":"Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S, et\u00a0al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. Ajr Am J Roentgenol. 2003;181:1115\u201324.","journal-title":"Ajr Am J Roentgenol"},{"key":"658_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1053\/j.semnuclmed.2007.02.009","volume":"37","author":"R Howman-Giles","year":"2007","unstructured":"Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007;37:286\u2013302.","journal-title":"Semin Nucl Med"},{"key":"658_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et\u00a0al. Sensitivity comparison of 68ga-OPS202 and 68ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J\u00a0Nucl Med. 2018;59:915\u201321.","journal-title":"J Nucl Med"},{"key":"658_CR26","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00259-013-2548-y","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between 68Ga-DOTA-TOC PET\/CT and 18F-DOPA PET\/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40:1800\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-018-0658-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-018-0658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-018-0658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:20:50Z","timestamp":1567538450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-018-0658-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":26,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s10354-018-0658-7","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"11 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.\u00a0Kroiss declares that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}